SFSara Ferreira

Sara Ferreira

*This is an algorithmically generated author record based on publicly available information.

Sara Ferreira has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PET/CT in the Evaluation of Hypoxia for Radiotherapy Planning in Head and Neck Tumors: Systematic Literature Review

    by Susana Isabel Lourenco Lopes, Sara Ferreira, Marco Caetano

    Introduction: PET/CT combines the molecular with the anatomical level which, with the administration of a hypoxia-sensitive radiopharmaceutical, allows the evaluation of tissue oxygenation. Materials and Methods: The work consists of a systematic literature review, including electronic addresses, books and articles dated from July 1997 to December 2019. The aim of this work is to identify the best suited PET radiopharmaceuticals for the detection of cell hypoxia and recognize the benefits for treatment planning with IMRT/VMAT techniques. Results: Hypoxia affects the likelihood cure of head and neck tumors, thereby reducing the success rate. Radiopharmaceuticals such as 18F-FMISO, 18F-FETNIM and 18F-HX4 allow the delineation of hypoxic subvolumes within the target volume to optimize IMRT/VMAT treatment. Discussion: The identification of hypoxia areas with PET/CT imaging and subsequent treatment with IMRT/VMAT allows a possible radiation dose escalation in radioresistant subvolumes. Conclusion: There is a decrease in relapses and an increased likelihood of disease-free survival.


  • Open Access

    Health-related Quality of Life and Utilities in Gastric Premalignant Conditions and Malignant Lesions: a Multicentre Study in a High Prevalence Country

    by Miguel Areia, Susana Alves, Daniel Brito, Ana Teresa Cadime, Rita Carvalho, Sandra Saraiva, Sara Ferreira, Joana Moleiro, António Dias Pereira, João Carrasquinho, et al.

    Background & Aims: A recent review of economic studies relating to gastric cancer revealed that authors use different tests to estimate utilities in patients with and without gastric cancer. Our aim was to determine the utilities of gastric premalignant conditions and adenocarcinoma with a single standardized health measure instrument.Methods: Cross-sectional nationwide study of patients undergoing upper endoscopy (n=1,434) using the EQ-5D-5L quality of life (QoL) questionnaire.Results: According to EQ-5D-5L, utilities in individuals without gastric lesions were 0.78 (95% confidence interval: 0.76-0.80), with gastric premalignant conditions 0.79 (0.77-0.81), previously treated for gastric cancer 0.77 (0.73-0.81) and with present cancer 0.68 (0.55-0.81). Self-reported QoL according to the visual analogue scale (VAS) for the same groups were 0.67 (0.66-0.69), 0.67 (0.66-0.69), 0.62 (0.59-0.65) and 0.62 (0.54-0.70) respectively. Utilities were consistently lower in women versus men (no lesions 0.71 vs. 0.78; premalignant conditions 0.70 vs. 0.82; treated for cancer 0.72 vs. 0.78 and present cancer 0.66 vs. 0.70).Conclusion: The health-related QoL utilities of patients with premalignant conditions are similar to those without gastric diseases whereas patients with present cancer show decreased utilities. Moreover, women had consistently lower utilities than men. These results confirm that the use of a single standardized instrument such as the EQ-5D-5L for all stages of the gastric carcinogenesis cascade is feasible and that it captures differences between conditions and gender dissimilarities, being relevant information for authors pretending to conduct further cost-utility analysis.Abbreviations: LYS: life-years saved; QALY: quality-adjusted life years; VAS: visual analogue scale; CI: confidence interval.